REFERENCES

• KorczynAD.Parkinson's disease. In: Davis KL, ed.Psychopharmacology; The Fourth Generation of Progress. New York, NY: Raven Press199414791485
   Google Scholar
• AgidY.AhlskogE.AlbaneseA.et al.Levodopa in the treatment of Parkinson's disease: a consensus meeting.Mov Disord.19991491191310584663
   PubMed Web of Science ®Google Scholar
• KorczynAD.Pathophysiology of drug-induced dyskinesias.Neuropharmacology.1973116016074275111
   PubMed Web of Science ®Google Scholar
• SternMB.The early treatment of Parkinson's disease: levodopa, DA agonists or both.Parkinsonism Relat Disord.20017273311008193
   PubMed Web of Science ®Google Scholar
• MarsdenCD.ParkesJD.“On-off” effects in patients with Parkinson's disease on chronic levodopa therapy.Lancet.1976129229655599
   PubMed Web of Science ®Google Scholar
• BrooksDJ.Advances in imaging Parkinson's disease.Curr Opin Neurol.1997103273319266157
   PubMed Web of Science ®Google Scholar
• RajputAH.MartinW.Saint HilaireMH.et al.Tolcapone improves motor function in parkinsonian patients with the “wearing off” phenomenon: a double-blind, placebo-controlled multicenter trial.Neurology.199749106610719339691
   PubMed Web of Science ®Google Scholar
• BrooksDJ.SagarH.UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomized, placebo-controlled, double-blind, six-month study.J Neurol Neurosurg Psychiatry.2003741071107912876237
   PubMed Web of Science ®Google Scholar
• KorczynAD.COMT inhibitors in Parkinson's disease. In: Factor SA, Weiner WJ, eds.Parkinson's Disease. New York, NY: Demos2002379397
   Google Scholar
• OlanowCW.StucchiF.COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?Neurology.200462S74S82
   Web of Science ®Google Scholar
• RascolO.GoetzC.KollerW.PoeweW.SampaioC.Treatment interventions for Parkinson's disease: an evidence based assessment.Lancet.20023591589159812047983
   PubMed Web of Science ®Google Scholar
• CalneDB.TeychennePF.ClaveriaLE.EastmanR.GreenacreJK.PetrieA.Bromocriptine in parkinsonism.BMJ.197444424444425916
   PubMed Web of Science ®Google Scholar
• MontastrucJL.RascolO.RascolA.A randomized controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3-year follow-up.J Neurol Neurosurg Psychiatry.1989527737752664089
   PubMed Web of Science ®Google Scholar
• RinneUK.Problems associated with long-term levodopa treatment of Parkinson's disease.Acta Neurol Scand.1983951926
   Google Scholar
• RascolO.BrooksDJ.KorczynAD.et al.A 5-year study of the incidence of dyskinesias in patients with early Parkinson's disease who were treated with ropinirole or levodopa.N Engl J Med.20003421484149110816186
   PubMed Web of Science ®Google Scholar
• LingLH.AhlskogJE.MungerTM.et al.Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.Mayo Clin Proc.19997437137510221467
   PubMed Web of Science ®Google Scholar
• Van CampG.FlamezA.CosynsB.et al.Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.Lancet.20043631179118315081648
   PubMed Web of Science ®Google Scholar
• KorczynAD.BruntER.LarsdenJR.et al.A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease.Neurology.19995336437010430427
   PubMed Web of Science ®Google Scholar
• JennerP.The rationale for the use of dopamine agonists in Parkinson's disease.Neurology.199545S6S127715795
   PubMed Web of Science ®Google Scholar
• LangeKW.Clinical pharmacology of dopamine agonists in Parkinson's disease.Drugs Aging.1998133813899829165
   PubMed Web of Science ®Google Scholar
• KorczynAD.Hallucinations in Parkinson's disease.Lancet.20013581031103211589931
   PubMed Web of Science ®Google Scholar
• OlanowCW.SchapiraAHV.RothT.Waking up to sleep episodes in Parkinson's disease.Mov Disord Soc.200015212215
   PubMed Web of Science ®Google Scholar
• SchapiraAH.Sleep attacks (sleep episodes) with pergolide.Lancet.20003551332133310776749
   PubMed Web of Science ®Google Scholar
• PalS.BhattacharyaKF.AgapitoC.et al.A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.J Neural Transm.2001108717711261748
   PubMed Web of Science ®Google Scholar
• FruchtS.RogersJD.GreenePE.et al.Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.Neurology.1999521908191010371546
   PubMed Web of Science ®Google Scholar
• FerreiraJJ.ThalamasC.MontastrucJL.et al.Levodopa monotherapy can induce “sleep attacks” in Parkinson's disease patients.J Neurol Neurosurg Psychiatry.2001248426427
   Google Scholar
• LundBC.NeimanRF.PerryPJ.Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.Pharmacotherapy.1999191437143810600093
   PubMed Web of Science ®Google Scholar
• RobertsJW.MouradianM.Ho SohnY.et al.D2 agonist N-0923 in the treatment of Parkinson's disease.Neurology.199444244
   Web of Science ®Google Scholar
• GancherST.NuttJG.WoodwardWR.Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.Mov Disord Soc.1995103743
   PubMed Web of Science ®Google Scholar
• OndoW.HunterC.AlmaguerM.et al.A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.Mov Disord.19991466466810435505
   PubMed Web of Science ®Google Scholar
• RascolO.BlinO.ThalamasC.et al.ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease.Ann Neurol.19994573674110360765
   PubMed Web of Science ®Google Scholar
• FinbergJP.WangJ.BankiewiczK.et al.Increased striatal production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.J Neural Transm.199852279285
   Google Scholar
• CohenG.SpinaMB.Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.Ann Neurol.1989266896902510589
   PubMed Web of Science ®Google Scholar
• Parkinson's Disease Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med.1993178125183
   Google Scholar
• EshelY.KorczynAD.Amantadine antagonism of oxotremorine effects.J Neural Transm.1979467983574156
   PubMed Web of Science ®Google Scholar
• KorczynAD.KerenO.EshelY.Effect of amantadine on pupillary diameter in mice.Israel J Med Sci.1982181451477068338
   PubMedGoogle Scholar
• FactorSA.MolhoES.Transient benefit of amantadine in Parkinson's disease: the facts about the myth.Mov Disord.19991451551610348482
   PubMed Web of Science ®Google Scholar
• Verhagen MetamanL.Del DottoP.van den MunckhofP.et al.Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.Neurology.199850132313269595981
   PubMed Web of Science ®Google Scholar
• RabeyJM.KorczynAD.Efficacy of memantine, and NMDA receptor antagonist in the treatment of Parkinson's disease.J Neural Transm.19924277282
   Web of Science ®Google Scholar
• TrevesTA.PaleacuD.RabeyJM.KorczynAD.Depression inventories in Parkinson's disease. In: Przuntek H, Kraus PH, Klotz P, Korczyn AD, eds.Instrumental Methods and Scoring in Extrapyramidal Disorders. Vienna, Austria: Springer19953143
   Google Scholar
• BohnenNI.KauferDI.IvancoLS.et al.Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.Arch Neurol.2003601745174814676050
   PubMed Web of Science ®Google Scholar
• GiladiN.ShabtaiH.GurevichT.BenbunanB.AncaM.KorczynAD.Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.Acta Neurol Scand.200310836837314616309
   PubMed Web of Science ®Google Scholar
• RabeyJM.TrevesTA.NeufeldMY.OrlovE.KorczynAD.Low-dose clozapine in the treatment of levodopa induced mental disturbances in Parkinson's disease.Neurology.1995454324347898690
   PubMed Web of Science ®Google Scholar
• FernandezHH.FriedmanJH.JacquesC.RosenfeldM.Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.Mov Disord.19991448448710348474
   PubMed Web of Science ®Google Scholar
• KorczynAD.Dopaminergic drugs in development for Parkinson's disease. In: Gordin A, Kaakkola S, Teravainen H, eds.Advances in Neurology, 91. Parkinson's Disease. Philadelphia, Pa: Lippincott Williams & Wilkins2003267271
   Google Scholar
• KorczynAD.Autonomic nervous system disturbances in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, ed.Advances in Neurology: Parkinson's Disease: Anatomy, Pathology Therapy. New York, NY: Raven Press1990463468
   Google Scholar